<DOC>
	<DOC>NCT02470429</DOC>
	<brief_summary>The purpose of this study is to compare SYSTANE® HYDRATION to Hyabak 0.15% based on total ocular surface staining scores (TOSS) at Day 42.</brief_summary>
	<brief_title>Evaluation of Clinical Outcomes After the Use of SYSTANE® HYDRATION</brief_title>
	<detailed_description>Subjects will first be dispensed preservative-free 0.9% saline eye drops (saline eye drops) to be used during the Run-in phase between Screening Visit and Day 0 (Visit 1). Subjects who qualify will be randomized in a 1:1 manner to receive either treatment with SYSTANE® HYDRATION Lubricant Eye Drops or Hyabak 0.15% Eye Drops.</detailed_description>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<mesh_term>Lubricant Eye Drops</mesh_term>
	<criteria>Willing and able to attend all study visits; Use of nonBAK (Benzalkonium Chloride) artificial tears at least once a day, for at least 3 months prior to Screening Visit; Diagnosis of Dry Eye (by a health care professional) for at least 3 months prior to Screening Visit; Other protocoldefined inclusion criteria may apply. Women of childbearing potential who are pregnant or breast feeding; Any hypersensitivity to the use of the study product formulations or an allergy to any ingredient(s) contained within product formulations; Ocular abnormalities in either eye that could adversely affect the safety or efficacy outcome; Active ocular infection (bacterial, viral, or fungal) or active inflammation not associated with dry eye; Use of chronic systemic medications: (prescription, over the counter, vitamins/supplements) on a stable dose for less than 30 days prior to Screening Visit, or any anticipated change in dosing regimen during the course of the study; History of ocular or intraocular surgery or serious ocular trauma in either eye within the past 6 months prior to Screening Visit; Any medical condition (systemic or ophthalmic) that may, in the opinion of the Investigator, preclude the safe administration of test article or safe participation in the study; Use of any topical ocular overthecounter or prescribed medications in either eye (with the exception of artificial tears/gels/ lubricants) 2 weeks prior to Screening Visit; Contact lens use within 2 weeks prior to Screening Visit and unwilling to avoid contact lens use during the course of the study; Unwilling to avoid use of additional artificial tears (other than study medication) throughout the study; Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>